The discovery of immune checkpoints on T-cells, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1), and using them as therapeutic targets marked a breakthrough in melanoma treatment [1]. This evidence concerns the gene PDCD1 and melanoma.